Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
ROCKVILLE, Md., April 24, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2018 after 5:00 p.m. ET on Tuesday, May 8, 2018.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to discuss the first quarter 2018 business results on Wednesday, May 9, 2018 at 9:00 a.m. ET. Following management’s prepared discussion and analysis, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | |
| International dial-in: | (970) 315-0267 | |
| Conference ID: | 1568978 | |
| Conference Call Name: | Supernus Pharmaceuticals First Quarter 2018 Earnings Conference Call |
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
